CPTM Pharmaceutical Canada Ltd (formerly 1163560 B.C. Ltd) (the “Company”) today announced the formation of its first European subsidiary in the Republic of Malta.
Cannapharm Technologies Malta Limited (“CPTM”) is the first step in the Company’s expansion program, across the European continent in general and the European Union (“EU”) in particular.
“The EU is the natural target for our international development strategy” said Bruce H. Gaston, Director of CPTM Pharmaceutical Canada Ltd. “Malta has been selected for its ideal positioning within the EU and its government’s forward-thinking attitude towards the development of emerging industries”.
The Company believes in long-term, sustainable growth, based on the latest technological advances. It adheres to and implements the strictest of standards in its productions, whilst maintaining a result-driven, qualitative approach to its pharmaceutical operations in Europe and Asia.
CPTM Pharmaceutical Canada Ltd's stated strategy is to develop local subsidiaries and partnerships in selected territories around the world, working closely with governments, regulatory authorities and local municipalities, to utilize, integrate and grow existing local infrastructures, within the framework of regional and governmental development programs and targets.
Bruce H. Gaston
About CPTM Pharmaceutical Canada Ltd
CPTM Pharmaceutical Canada Ltd (formerly 1163560 B.C. Ltd) is a Canadian entity, incorporated under the Business Corporations Act in the province of British Columbia, Canada.